Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A new verdict for an old convict.

G P Pfeifer

    Nature Genetics
    |August 31, 2001
    PubMed
    Summary

    Wild-type Kras2 acts as a tumor suppressor, counteracting the effects of mutated Kras2. This finding challenges the established view of Kras2 as solely a dominant oncogene in cancer development.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Genome-wide DNA methylation profiling reveals cancer-associated changes within early colonic neoplasia.

    Oncogene·2017
    Same author

    [Intrinsic factors, genes, and skin aging].

    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2016
    Same author

    The DNA methylation landscape of small cell lung cancer suggests a differentiation defect of neuroendocrine cells.

    Oncogene·2012
    Same author

    Genomic footprinting by ligation mediated polymerase chain reaction.

    Methods in molecular biology (Clifton, N.J.)·2011
    Same author

    Loss of Rassf1a enhances p53-mediated tumor predisposition and accelerates progression to aneuploidy.

    Oncogene·2010
    Same author

    RASSF1A interacts with and activates the mitotic kinase Aurora-A.

    Oncogene·2008

    Area of Science:

    • Oncology
    • Molecular Biology
    • Genetics

    Background:

    • Kras2 mutations are frequently observed in human cancers and carcinogen-induced rodent tumors.
    • The activated form of Kras2 has been traditionally characterized as a dominant oncogene driving tumor formation.

    Discussion:

    • This study reveals that wild-type Kras2 possesses tumor suppressor properties.
    • Wild-type Kras2 can mitigate the transforming potential of oncogenically activated ras, suggesting a dual role.

    Key Insights:

    • The conventional understanding of Kras2 as exclusively an oncogene is challenged.
    • Wild-type Kras2 functions as a suppressor of oncogenic transformation mediated by mutated Kras2.
    • This suggests a complex regulatory mechanism involving Kras2 in tumorigenesis.

    Outlook:

    • Further research into the dual role of Kras2 could reveal novel therapeutic strategies targeting cancer.
    • Understanding the interplay between wild-type and mutated Kras2 may lead to new approaches for cancer prevention and treatment.

    Related Experiment Videos